Tau-protein, fosforylovaný tau-protein a beta-amyloid42 v likvoru u demencí a roztroušené sklerózy
| Title in English | Total and Phosphorylated Tau-protein and Beta-Amyloid42 in Cerebrospinal Fluid in Dementias and Multiple Sclerosis |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská neurologie a neurochirurgie |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | Alzheimer's disease; Creutzfeldt-Jakob disease; multiple sclerosis; beta-amyloid42; total tau-protein; phosphorylated tau-protein |
| Description | Introduction: Differential diagnosis of dementias is often difficult, and for this reason research into biomarkers that can assist in the diagnostic process has lately become important. The current study focuses on the diagnostic value of beta-amyloid42 (Abeta-42), overall tau protein and phosphorylated tau protein for the diagnosis of Alzheimer's disease (AD), Creutzfeldt-Jakob disease (CJD) and multiple sclerosis (MS). Methods: 18 patients diagnosed as having AD according to NINCDS-ADRDA criteria, 16 patients with isolated clinical syndrome suspected of MS (7 of them fulfilling McDonald's criteria) and 3 patients with CJD (WHO criteria) were included into study together with a cognitive intact control group consisting of 38 individuals. A curve analysis for receiver operating characteristics (ROCs) was calculated to define the cut off concentrations for the biomarkers and the maximum sensitivity and specificity for the given group. Correlation was used in the final analysis. Results: in patients diagnosed with AD there was significant decrease of beta-amyloid42 level (616,5 pq/ml,p<0,0001) and increase of tau protein level (451 pq/ml, p=0,0003) compared to control group. In CJD there was marked elevation of tau protein level and increased total tau versus phosphorylated tau protein ratio in comparison with the AD group as well as the control group. No significant changes in biomarker levels were found for patients with MS. Conclusion: Our results are in line with the current literature on the value of the three biomarkers mentioned above in the differential diagnosis of AD and CJD. We have not found any such evidence in relation to MS. |
| Related projects: |